{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:11:01Z","timestamp":1764785461982,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1245\/s10434-024-16159-y","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T20:17:56Z","timestamp":1725999476000},"page":"9272-9280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Isolated Limb Infusion for Limb-Threatening Sarcomas"],"prefix":"10.1245","volume":"31","author":[{"given":"Shaliz","family":"Aflatooni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleena","family":"Boby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helana","family":"Ghali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle K.","family":"DePalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Mahrukh Hussnain","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Mullinax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6886-4468","authenticated-orcid":false,"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"16159_CR1","unstructured":"World Health Organization W, Fletcher C, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours. 4th ed. Washington, D.C.: World Health Organization, 2013."},{"key":"16159_CR2","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/1097-0142(19900415)65:8<1727::AID-CNCR2820650811>3.0.CO;2-X","volume":"65","author":"B R\u00f6\u00f6ser","year":"1990","unstructured":"R\u00f6\u00f6ser B, Gustafson P, Rydholm A. Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma? Cancer. 1990;65:1727\u20139.","journal-title":"Cancer"},{"key":"16159_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00000658-198209000-00009","volume":"196","author":"SA Rosenberg","year":"1982","unstructured":"Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196:305\u201315.","journal-title":"Ann Surg"},{"key":"16159_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00000658-199203000-00012","volume":"215","author":"WC Williard","year":"1992","unstructured":"Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg. 1992;215:269\u201375.","journal-title":"Ann Surg"},{"key":"16159_CR5","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","volume":"14","author":"AM Eggermont","year":"1996","unstructured":"Eggermont AM, SchraffordtKoops H, Li\u00e9nard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14:2653\u201365.","journal-title":"J Clin Oncol"},{"key":"16159_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1245\/ASO.2005.03.059","volume":"12","author":"DJ Gr\u00fcnhagen","year":"2005","unstructured":"Gr\u00fcnhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol. 2005;12:473\u20139.","journal-title":"Ann Surg Oncol"},{"key":"16159_CR7","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1245\/s10434-008-0045-5","volume":"15","author":"MD Moncrieff","year":"2008","unstructured":"Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2008;15:2749\u201356.","journal-title":"Ann Surg Oncol"},{"key":"16159_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jamcollsurg.2016.12.035","volume":"224","author":"JE Mullinax","year":"2017","unstructured":"Mullinax JE, Kroon HM, Thompson JF, et al. Isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma. J Am Coll Surg. 2017;224:635\u201342.","journal-title":"J Am Coll Surg"},{"key":"16159_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","volume":"148","author":"O Creech Jr","year":"1958","unstructured":"Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616\u201332.","journal-title":"Ann Surg"},{"key":"16159_CR10","doi-asserted-by":"publisher","first-page":"108050","DOI":"10.1016\/j.ejso.2024.108050","volume":"50","author":"AJ Hayes","year":"2024","unstructured":"Hayes AJ, Coker DJ, Been L, et al. Technical considerations for isolated limb perfusion: a consensus paper. Eur J Surg Oncol. 2024;50:108050.","journal-title":"Eur J Surg Oncol"},{"key":"16159_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<238::AID-SSU8>3.0.CO;2-9","volume":"14","author":"JF Thompson","year":"1998","unstructured":"Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238\u201347.","journal-title":"Semin Surg Oncol"},{"key":"16159_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/jso.23540","volume":"109","author":"HM Kroon","year":"2014","unstructured":"Kroon HM, Huismans A, Waugh RC, Kam PC, Thompson JF. Isolated limb infusion: technical aspects. J Surg Oncol. 2014;109:352\u20136.","journal-title":"J Surg Oncol"},{"key":"16159_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/02656730701805520","volume":"24","author":"MG M\u00f6ller","year":"2008","unstructured":"M\u00f6ller MG, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperth. 2008;24:275\u201389.","journal-title":"Int J Hyperth"},{"key":"16159_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/archsurg.2011.139","volume":"146","author":"KK Turaga","year":"2011","unstructured":"Turaga KK, Beasley GM, Kane JM III, et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg. 2011;146:870\u20135.","journal-title":"Arch Surg"},{"key":"16159_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/02656736.2012.740548","volume":"29","author":"NA Vohra","year":"2013","unstructured":"Vohra NA, Turaga KK, Gonzalez RJ, et al. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperth. 2013;29:1\u20137.","journal-title":"Int J Hyperth"},{"key":"16159_CR16","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1245\/s10434-017-6107-9","volume":"24","author":"C O\u2019Donoghue","year":"2017","unstructured":"O\u2019Donoghue C, Perez MC, Mullinax JE, et al. Isolated limb infusion: a single-center experience with over 200 infusions. Ann Surg Oncol. 2017;24:3842\u20139.","journal-title":"Ann Surg Oncol"},{"key":"16159_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000495888","volume":"35","author":"J Teras","year":"2019","unstructured":"Teras J, M\u00e4gi A, Teras M, et al. Soft tissue cancer management: isolated limb infusion for sarcoma. Visc Med. 2019;35:373\u20139.","journal-title":"Visc Med"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16159-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16159-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16159-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:05:56Z","timestamp":1731071156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16159-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":17,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["16159"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16159-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Jonathan S. Zager has received payments from Delcath Systems\u2013Medical Advisory Board. He has consulting agreements with Philogen, Merit Medical, Castle Biosciences, and Merck. His department receives research funding from\u00a0Philogen, SWOG, Delcath Systems, and Provectus. Moffitt Cancer Center has licensed Intellectual Property (IP) related to the proliferation and expansion of tumor-infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Dr. Mullinax (J.E.M.), an inventor of such intellectual property, participates in sponsored research agreements with Iovance Biotherapeutics, Intellia Therapeutics, and SQZ Biotech that are not related to this research, and has received research support not related to this research from NIH-NCI (K08CA252642), Ocala Royal Dames, and V Foundation. Dr. Mullinax has received ad hoc consulting fees from Merit Medical and Iovance Biotherapeutics. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Shaliz Aflatooni, Dr. Michelle M. Dugan, Aleena Boby, Helana Ghali, Dr. Danielle K. DePalo, and Dr. Syeda Mahrukh Hussnain Naqvi have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}